A cost-utility analysis of oral triptans for migraine in an adult outpatient setting in Japan between FY2018, 2020, and 2022.

Background: Migraine is characterized by severe headaches and nausea that interfere with daily life activities, resulting in productivity loss associated with economic challenges. However, no studies have conducted an economic evaluation of migraine treatment with triptans in Japan. Additionally, a drug price reduction system in Japan has been pointed out as having some problems.
Objective: This study aims to determine the cost effectiveness of oral triptans, including eletriptan, naratriptan, rizatriptan, sumatriptan, and zolmitriptan, in treating migraines among adults in an outpatient setting in Japan using cost resources in fiscal year (FY) 2018, FY2020, and FY2022.
Methods: A cost-utility analysis was conducted for healthcare payers, focusing on Japanese patients (>18 years old) experiencing migraines. The study employed a base-case model using probabilities derived from a network meta-analysis. Direct costs involved medical and drug costs (2018, 2022, and 2022 versions). Effe..., , , # A Cost-Utility Analysis of Oral Triptans for Migraine in an Adult Outpatient Setting in Japan between FY2018, 2020, and 2022.

---

### Author(s)

Naoto Nakagawa, Phar.D., Ph.D.
School of Pharmaceutical Sciences, Ohu University, Koriyama, Fukushima, Japan
31-1 Misumido, Tomita-machi, Koriyama, Fukushima 963-8611, Japan
Email:

Mizuha Konno, BS, RPh
School of Pharmaceutical Sciences, Ohu University, Koriyama, Fukushima, Japan
31-1 Misumido, Tomita-machi, Koriyama, Fukushima 963-8611, Japan
Email: <[e-mail]>

Masami Kashiwabara, B.S., R. Ph,
QOL pharmacy
Email:

Shinya Shimoji, PhD
Shimoji Neurology Clinic
Email:

Jun Mochimaru, BS, RPh
QOL pharmacy
Email:

Tadao Inoue, Ph.D.
Yamagata University Faculty of Medicine
Email:

Leanne Lai, Ph.D.
College of Pharmacy, Kaohsiung Medical University, Kaohsiung City, Taiwan
Email:

### **File list**

Input data for FY2018
Input data for FY2020

Input data for FY2022

Input data for probabilistic sensitivity analysis for FY2018

...